Clinical trial registry record

Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Active Not Recruiting.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated May 22, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06752694
Last registry update
May 22, 2026
Status
Active Not Recruiting
Phase
Phase 2
Sponsor
Fred Hutchinson Cancer Center
Enrollment
1
Countries
United States
Match confidence
70%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
1
Population
ALL · 18 Years
Duration
2025-09-25 to 2026-10-15
Intervention
Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Bone Marrow Transplantation; Computed Tomography; Cyclosporine; Fludarabine; Granulocyte Colony-Stimulating Factor; Mycophenolate Mofetil; Peripheral Blood Stem Cell Transplantation; Ruxolitinib; Sirolimus; Total-Body Irradiation; Multigated Acquisition Scan; Echocardiography
Comparator
Not reported
Outcomes measured
Incidence of grades II-IV acute graft-versus-host disease (GVHD) — At day 100; Incidence of grade III-IV acute GVHD — At day 100; Incidence of chronic GVHD — At 1 year; Incidence of primary graft failure — At 2 years; Nonrelapse mortality — At day 100; Overall survival — At 1 year
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 70% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Rapamycin · 70%Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

rapamycin
Read the original source →Export JSON